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Background: Urinary tract infections (UTIs) are among the most common infectious diseases and drivers of
antibiotic use and in-hospital days. A reduction of antibiotic use potentially lowers the risk of antibiotic resistance.
An early and adequate risk assessment combining medical, biopsychosocial and functional risk scores has the
potential to optimize site-of-care decisions and thus allocation of limited health-care resources. The aim of this
factorial design study is twofold: first, for Intervention A, it investigates antibiotic exposure of patients treated with a
protocol based on the type of UTI, procalcitonin (PCT) and pyuria. Second, for Intervention B, it investigates the
usefulness of the prognostic biomarker proadrenomedullin (ProADM) integrated into an interdisciplinary assessment
bundle for site-of-care decisions.
Methods and design: This randomized controlled open-label trial has a factorial design (2 × 2). Randomization of
patients will be based on a pre-specified computer-generated randomization list and independent for the two
interventions. Adults with UTI presenting to the emergency department (ED) will be screened and enrolled after
providing informed consent.
For our first Intervention (A), we developed a protocol based on previous observational research to recommend
initiation and duration of antibiotic use based on the clinical presentation of UTI, pyuria and PCT levels. For our
second intervention (B), an algorithm was developed to support site-of care decisions based on the prognostic
marker ProADM and distinct nursing factors on days 1 and 3. Both interventions will be compared with a control
group conforming to the guidelines.
The primary endpoints for the two interventions will be: (A) overall exposure to antibiotics and (B) length of
physician-led hospitalization within a follow-up of 30 days. Endpoints are assessed at discharge from hospital, and
30 and 90 days after admission. We plan to screen 300 patients and enroll 250 for an anticipated estimated loss of
follow-up of 20%. This will provide adequate power for the two interventions.
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Discussion: This trial investigates two strategies for improved individualized medical care in patients with UTI. The
minimally effective duration of antibiotic therapy is not known for UTIs, which is important for reducing the
selection pressure for antibiotic resistance, costs and drug-related side effects. Triage decisions must be improved
to reflect the true medical, biopsychosocial and functional risks in order to allocate patients to the most appropriate
care setting and reduce hospital-acquired disability.
Trial registration: ISRCTN13663741Background
Urinary tract infections (UTIs) include acute cystitis
(involving the lower urinary tract) and acute pyeloneph-
ritis (involving the upper urinary tract). If a structural or
functional abnormality is present, the UTI is consi-
dered ‘complicated’, implying a higher risk of encoun-
tering antimicrobial resistance and therapy failure [1].
Escherichia coli has been identified as the most common
causative pathogen in uncomplicated (75%) as well as in
complicated UTIs (40% to 50%) [2].
Current empiric antibiotic therapy schemes for UTIs
are based on guidelines that largely reflect expert opin-
ion [3,4]. There are few intervention studies comparing
different durations of antibiotic therapy [5-7]. Consider-
ing the emerging antibiotic resistance of uropathogens
[2,8,9] and the growing awareness of the epidemiological
side effects of antibiotics [10], efforts aimed at improve-
ments should be intensified.
There is increasing interest in biomarkers as diagnostic
and prognostic factors in infectious diseases since they
reflect the host’s response and are objective, dynamic
and easily measurable. In particular, the biomarker
procalcitonin (PCT) has been thoroughly investigated
and has been proven to be a useful tool in managing the
antibiotic therapy of bacterial infections of the respira-
tory tract [11,12]. In a previous multicenter study of pa-
tients with sepsis admitted to French intensive care
units (ICUs), a PCT-guided strategy for treating bacterial
infections safely reduced antibiotic exposure compared
to present guidelines [13]. Of note, 7% of the enrolled
patients had a UTI as their source of infection. PCT pri-
marily indicates systemic infections. Thus, in patients
with UTIs, PCT likely needs to be combined with in-
flammatory surrogates of local infection [14] such as py-
uria or a urinary protein profile. The normalization of
pyuria or a drop of at least 90% in urinary leukocytes
correlated with a successful outcome of UTI therapy
[15]. The tubular injury marker, the α1-microglobulin/
creatinine ratio, has a high specificity and sensitivity in
distinguishing pyelonephritis from cystitis and is posi-
tively correlated with baseline C-reactive protein (CRP)
levels [16-18].
Radiologic evaluation of the urinary tract in patients with
a febrile UTI is frequently performed. The EuropeanAssociation of Urology recommends ultrasound evaluation
to rule out obstruction and renal stone disease. Additional
radiologic testing (for example, computed tomography, ex-
cretory urogram or 99mTechnetium-dimercaptosuccinic
acid scan) ‘should be considered’ if fever persists after 72 h
of treatment [19]. A more selective approach to imaging
using a clinical prediction rule has been advocated [20].
Contrast-enhanced ultrasound (CEUS) is a promising
method for detecting acute pyelonephritis [21]. Its sensitiv-
ity and specificity might approach that of computed tom-
ography [22], but the available data are very limited.
In adults ≥65 years, UTIs are the second most common
cause for hospitalization among infectious diseases [23]
with an annual cost of approximately $1.6 billion in the
USA alone [24]. Older patients have a high risk of becom-
ing functionally impaired or lose their self-care abilities if
they are hospitalized [25], possibly leading to further in-
patient treatment or an increased length of stay (LOS)
whereas outpatient treatment is less expensive [26] and car-
ries a lower risk of subsequent disability. Particularly for
lower respiratory tract infections (LRTIs), many patients
are hospitalized for fear of medical complications [27] or
for medical co-morbidities, functional and psychosocial
reasons, despite a low-risk classification according to clin-
ical severity scores [26,28]. Accordingly, one-fifth of low-
risk inpatients with community acquired pneumonia (CAP)
do not have any contraindications for outpatient treatment
or identifiable risk factors for hospitalization [28]. Multidis-
ciplinary assessment in order to triage to the most appro-
priate care setting [29-31], as well as innovative pathway
bundles are important in reducing the hospitalization rate,
LOS, antibiotic use and overall costs while achieving similar
quality of life and patient outcomes as explored for LRTI
[32,33]. For UTIs equivalent studies are lacking so far, but
as evident in daily clinical practice, improved triage for
these infections is urgently needed. For LRTI we showed
that ProADM was the most accurate biomarker for prog-
nostic assessment [31,34,35]. As it is not specific for LRTIs,
we propose that ProADM will be an excellent marker for
prediction of re-hospitalization and death in UTIs [36].
Methods
This is a randomized controlled open-label trial using a
two-by-two factorial study design with two independent
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antibiotic part and one for the triage part, respectively)
(Figure 1). The objectives are first, for Intervention A, to
analyze the efficacy and safety of a PCT- and pyuria-
guided antibiotic therapy in individualizing and reducing
the duration of antibiotic treatment compared to the
guidelines [4,10,19,37] and second, for Intervention B, to
test the impact on LOS of ProADM-enhanced triage de-
cisions compared to standard care. Both interventions
are for a high-intensity implementation of interdisciplin-
ary risk assessment for triage in patients with UTIs pre-
senting to an ED. LOS is defined as the number of days
of physician-led hospitalization until discharge to ambu-
latory or nurse-led care.
The trial is supervised by an independent safety moni-
toring board, which is not involved in the design and
conduct of the trial. The board consists of three experts
in internal medicine, infectious diseases, nephrology and
epidemiology, respectively.
Ethical approval for this trial, which is in compliance
with the Helsinki Declaration and in agreement with the
CONSORT statement [38], has been obtained from the
local ethical committee. The institutional review board
of the Canton Aargau approved the study protocol. All
participating patients or their relatives must give written
informed consent.
Setting
In April 2012, we started to screen all adult patients
with a suspected UTI admitted to the ED of the public
Cantonal Hospital of Aarau, a tertiary-care 600-bed
hospital in northern Switzerland. We expect to finish
the study by December 2014.
Physicians in charge of patient recruitment and inclu-
sion and nursing staff attended a structured seminar on
evidence-based guidelines for the management of pa-
tients with UTIs, the details of the protocol, the ration-
ale and the design of the trial and the online website.
Participants
Inclusion criteria for patients are age ≥18 years and ad-
mission from the community or a nursing home with a
main diagnosis of acute UTI (that is, symptoms less than
28 days). Exclusion criteria are other infections that re-
quire an antibiotic therapy, pre-treatment with antibi-
otics within the last 48 h, pregnancy, prostatitis (defined
as pain on digital rectal examination or a Prostate-
speicifc antigen (PSA) > 4 ng/ml or PSA > 2× baseline)
presence of implanted foreign bodies in the urinary tract
or urinary catheters, endovascular prostheses or foreign
bodies, non-endovascular prostheses or foreign bodies
within 6 months after implantation, insufficient language
skills with no possibility for translation, foreseeable non-
compliance for follow-up (for example, current drugabuse), severe immunodeficiency (neutrophiles <500/μL,
CD4 cells <350/μL in patients with HIV infection, leu-
kemia, lymphoma, myeloma, cytotoxic medications,
hemodialysis, transplant patients) or severe medical
co-morbidity with imminent death.
Definitions
UTI is defined by at least one clinical symptom (core body
temperature ≥38.0°C, urinary urgency, polyuria, dysuria,
suprapubic pain, flank pain, costovertebral angle tender-
ness, nausea and vomiting) and one urinary criterion
(pyuria >20 leukocytes/μl [39] and/or nitrites). A UTI is de-
fined as febrile UTI/pyelonephritis if there is flank pain,
costovertebral angle tenderness or a body temperature
≥38°C, and otherwise as simple UTI. A UTI is defined as
complicated if any of the following criteria are fulfilled:
male gender, age >70 years, symptoms >7 days, recent anti-
biotic therapy (within 30 days), recurrent UTIs (two or
more during the last 6 months or three during the last
12 months), recent urologic intervention (30 days), func-
tional or anatomic abnormality, diabetes mellitus or im-
munosuppressive therapy; otherwise UTI is considered
uncomplicated for example, young non-pregnant women.
Randomization
Randomization of patients to either intervention is based
on a pre-specified computer-generated randomization
list and concealed by using a centralized password-
secured website. Based on the factorial design, the two
randomizations are independent.
Interventions
With enrollment of each patient, the physician in charge
is reminded of the processes of care in the ED. The rec-
ommendations include the choice of antibiotic therapy
and duration as well as site-of-care decisions, together
with reminders about biopsychosocial and functional
overruling criteria and medical risk.
Intervention A
Appropriate antibiotics and minimal duration of antibiotic
treatment are based on recent guidelines [10] after local
adaptation by a panel of experts. PCT is used to guide
antibiotic treatment (Figure 2). We use fosfomycin (3 g
single dose) [40] and trimethoprim-sulfamethoxazole
(800/160 mg twice daily) for simple UTIs. Furthermore
we use ciprofloxacin orally (500 mg twice daily or 250 mg
twice daily if the estimated glomerular filtration rate
<30 ml/min/1.73 m2) or ceftriaxone intravenously (2 g
daily) for febrile UTIs/pyelonephritis. If known, previous
antibiotic resistant profiles are considered. If there is a
non-susceptible urine pathogen in the current urine cul-
ture the antibiotic therapy is adjusted. In inpatients, anti-
biotic duration is based on absolute values of PCT and
Figure 1 Trial overview. D1: day 1; D3: day 3; D5: day 5; D7: day 7; D30: day 30.
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Figure 2 Individualized antibiotic guidance by PCT and pyuria. The algorithm for diagnostic purposes is shown. If there is any concern
about microbiologic resistance, therapy extension is considered. For proven microbiologic resistance therapy is adjusted. Remaining antibiotic
treatment after patient discharge is guided by last PCT value to result in total antibiotic duration in analogy to outpatient treatment. Abx:
antibiotics; GFR: estimated glomerular filtration rate with MDRD formula; ICU: intensive care unit; NSAIDs: nonsteroidal anti-inflammatory drugs;
PCT: procalcitonin; TMP-SMX: trimethoprim-sulfamethoxazole; UST: urinalysis; UTI: urinary tract infection.
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the antibiotic duration is based on absolute values of PCT
only. PCT and pyuria are measured on admission, and, in
hospitalized patients, every other day as long as the patient
receives antibiotics for the UTI. Pyuria criteria are derived
from local data on female patients with UTIs [15]. PCT
cutoffs are derived from data from our recent observa-
tional study and after extrapolation from patients with
LRTIs and sepsis [36,41,42]. Patients with uncomplicated
simple UTIs in the PCT group receive NSAIDs regardless
of PCT values for symptom resolution given emerging
data [43,44]. In the control group, antibiotic durations are
recommended based on guidelines (Figure 2).Since failure of pyuria to decrease at least 90% within
24 h of antibiotic therapy was associated with treatment
failure in patients with lower UTIs [15], we collect a urine
specimen after 48 h (day 3) of antibiotic therapy in all pa-
tients. If patients are already at home at this time, they are
given a container for urine to be returned for a urinalysis
including determination of pyuria (Figure 1). We also col-
lect urine for urinalysis and urine culture on day 7 after
end of therapy, day 30 after enrollment, and in case of re-
currence within 90 days. The patients are instructed to
collect clean midstream urine into sterile urine containers.
A vacuum is used to transfer the urine from the container
to special urine tubes: BD VacutainerW Plus Preservative
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hexidine preservatives for urinalysis and BD VacutainerW
Plus C&S Preservative Tube with boric acid, sodium for-
mate and sodium borate for urine culture. These urine
specimens are sent by priority mail in prestamped enve-
lopes immediately after collection. Priority mail requires
typically less than 24 h (maximum 48 h) to arrive at our
hospital laboratory.
Intervention B
The triage decision in the ED is based on an interdisciplin-
ary biopsychosocial and functional risk assessment by the
treating physician (for medical risk) and the ED nursing
team (for biopsychosocial risk) (Figure 3). Hospitalization
criteria in the control group include: 1. severe illness, high
fever (≥39°C), costovertebral angle tenderness or flank
pain; 2. inability to take oral medications or fluids; dehy-
dration; 3. questionable patient compliance; 4. complica-
tions of pyelonephritis and 5. co-morbidities. In the
ProADM group, the subjective admission criterion 1 (se-
vere illness, high fever, costovertebral angle tenderness, se-
verely impaired health) is omitted (simple UTI) or replaced
by objective ProADM cutoffs for patients with febrile UTI/
pyelonephritis. In patients with simple UTI, we do not ex-
pect the ProADM levels to provide sufficient prognostic in-
formation and therefore do not include ProADM in their
admission criteria. A standardized score (the post-acute
care discharge score, PACD) [45] is used to stratify all pa-
tients as low or high risk for subsequent rehabilitation and
care. The final triage decision is a consensus by physicians,
nurses and patient (or relatives). If a consensus cannot be
reached, the patient’s preference has priority.
The clinical risk assessment of both doctors and nurses
is standardized using medical stability criteria [46] and
biopsychosocial and functional scores (Selbstpflegeindex
(SPI) self-care index [45,47]) and is used to assess the suit-
ability of patients for discharge from the hospital (Figure 4).
The care and risk assessment bundle is implemented in
both groups using behavioral and communication strat-
egies proven to be highly effective [48].
Levels of ProADM are measured on admission and on
day 3. ProADM cutoff tertiles derived from patients
with LRTI will be used for severity assessment [41]:
<0.75 nmol/l; 0.75 to 1.5 nmol/l; >1.5 nmol/l. Physicians
receive detailed information on how to interpret
ProADM cutoffs and about the results from previous
trials when ProADM was used in patients with
LRTI [12,29,31,34,35,49-51]. ProADM is measured
in an ethylenediaminetetraacetic acid (EDTA) plasma by
a sandwich immunoassay (MR-ProADM, BRAHMS AG,
Hennigsdorf, Germany) with an analytical detection limit
of 0.08 nmol/l and a functional assay sensitivity of
0.12 nmol/l. It is available within 1.5 h upon ordering
(24 h a day, daily).Reassessment of the possibility for discharge from the
acute-care hospital is based upon reaching medical sta-
bility at any time plus appropriate ProADM levels with
particular emphasis on assessment on day 3 (Figure 4).
On day 3, the treating physicians receive recommenda-
tions regarding discharge according to the clinical stabil-
ity algorithm. Guidelines are displayed on handouts
given to the treating physicians. Algorithm compliance
is controlled by the study team and reasons for non-
compliance are documented.
Discharge planning based on the biopsychosocial risk
at admission (PACD ≥ 8) is initiated immediately and
any need for action discussed at each round.
Patients with low medical risk or medically stabilized
but high biopsychosocial requirements can be triaged to
nurse-led care. The nursing staff is in charge of further
management with medical input only at further request
or if there is a medical deterioration.
Medically stable patients not fulfilling medical criteria
and biopsychosocial, functional and organizational over-
ruling criteria (see section “Overruling criteria for anti-
biotic treatment and hospitalization”) are conside-
red suitable for discharge to home. Patients meeting
biopsychosocial or functional overruling criteria and
organizational criteria (waiting for a transfer to the non-
acute setting) are referred to non-acute medical care
(nurse-led care, health resort, rehabilitation, transitional
care or long-term care) (Figure 4).
Overruling criteria for antibiotic treatment and
hospitalization
Medical overruling criteria for prolonged antibiotic
therapy
1. Admission to ICU
2. Life-threatening co-morbidity
3. Complications: abscess, papillary necrosis,
emphysematous pyelonephritis, acute renal failure
(GFR < 30 ml/min or creatinine increase ≥50% from
baseline level)
Medical overruling criteria for hospitalization
1. Admission to ICU
2. Life-threatening co-morbidity
3. Complications: pyelonephritis, acute renal failure
(GFR < 30 ml/min or creatinine increase ≥50% from
baseline level)
4. Antibiotics or hospitalization (regardless of
indication) within the last week
5. Confusion, delirium or intravenous drug abuse
Biopsychosocial and functional overruling criteria for
hospitalization
Figure 3 Risk assessment on admission - site-of-care decisions (ProADM on admission). ICU: intensive care unit; PACD: post-acute care
discharge score; ProADM: proadrenomedullin; UTI: urinary tract infection.
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inability to reliably take medications
2. SPI score <32 (during hospitalization)
3. Deficit of mobility
Organizational overruling criteria for hospitalization
1. Waiting for results that may alter the management,
lab controls, investigations or therapy2. Waiting for relocation to a non-acute medical care
facility
3. Weekend or night
Preferences of the patient and the relatives
1. Patient and relatives concern about safety at home
2. Lack of nursing care
3. Financial reasons
Figure 4 Risk assessment during hospitalization - site-of-care decisions (ProADM on day 3). ICU: intensive care unit; PACD: post-acute care
discharge score; SPI: Selbstpflegeindex self-care deficit score; UTI: urinary tract infection.
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Urine sediment analysis, urine culture with an anti-
biotic resistance profile and urinary protein profile
(α1-microglobulin/creatinine ratio) are performed on
admission. In patients with a diagnosis of febrile UTI/
pyelonephritis, blood cultures are taken prior to administra-
tion of antibiotics. These patients also receive an ultrasound
evaluation of the urinary tract, including Doppler examin-
ation as well as a CEUS examination of both kidneys.
Chargeable and effective costs will be gathered from
the finance and controlling departments to calculatecosts per patient from study entry until discharge to a
non-hospital setting. Data on outcome and complica-
tions will be collected by the study team.
All patients are called by members of the study team
(who are unaware of the randomization group) on days
30 and 90 after randomization to inquire about clinical
recurrences, antibiotic side effects and the preparedness
for discharge [52] using a questionnaire with a ten-point
Likert scale response format. Interviews are standardized
according to a protocol and interviewers receive formal
introductory training.
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monitored. Since it is not feasible to have ProADM and
PCT values blinded in the control groups, however, algo-
rithm compliance is reinforced according to assigned
groups by the study team.
Both contrast-enhanced ultrasound criteria and urin-
ary protein profiles are used together with urine and
clinical criteria and biomarker levels for the final classifi-
cation as upper or lower UTI. For final analysis, culture
confirmation will be required (Table 1).
Healthcare-related quality of life on the day of discharge
is measured with the EQ-5D questionnaire. EQ-5D in-
cludes the 15-item EQ-5D self-classifier, which assesses
the health-related quality of life among five dimensions
and the EQVas, which obtains a self-rating of the current
health-related quality of life [53].
Outcomes and adverse events
The primary endpoint for Intervention A is overall ex-
posure to antibiotics in the PCT and pyuria guidance
group compared to the control group. Endpoints are
assessed at discharge from hospital, and 30 and 90 days
after admission. As secondary endpoints, we will com-
pare the PCT-pyuria group with the control group
regarding:
A. Clinical and microbiological cure 7 days after end of
therapy.
B. 30-day rate of clinical and microbiological
recurrence.
C. 90-day rate of clinical and microbiological
recurrence.
D. Antibiotic-associated side effects.
Regardless of group assignment, we will investigate:
E. The relationships of pyuria, urine culture cutoffs and
urinary α1-microglobulin/creatinine ratio with the
presence of pyelonephritis and level of biomarkers
(CRP, PCT, ProADM, and other biomarkers such as
urea, natriuretic peptides (ANP, BNP), copeptin,
endothelin, apoprotein A1).Table 1 Urine culture cutoffs for significance
Diagnosis Criteria
Uncomplicated, simple UTI ≥103 cfu/ml
Uncomplicated febrile UTI/pyelonephritis ≥104 cfu/ml
Complicated UTI (simple or febrile UTI/pyelonephritis)
in women ≥105 cfu/ml
in men ≥104 cfu/ml
in straight catheter urine ≥104 cfu/ml
cfu: colony-forming unit; UTI: urinary tract infection.F. Correlation between sonographic signs of
pyelonephritis and diagnosis based on urine culture
cutoffs, clinical criteria and biomarkers.
Our hypothesis for the secondary endpoints A to C is
that there is no difference between the two study groups.
Our hypothesis for endpoints E and F is that urinary
markers and contrast-enhanced ultrasound correlate with
systemic biomarkers and diagnosis of pyelonephritis.
For the primary endpoint for Intervention B, we assess
the length of physician-led hospitalization in the
ProADM-guided triage group compared to the control
group within a follow-up of 90 days. As secondary end-
points, we will compare the ProADM group with the
control group regarding:
A. resource utilization, defined as the length of index
hospitalization (physician- and/or nurse-led); rate
and length of re-hospitalization; rate of general
practitioner visits; rate of medical investigations and
interventions related to UTI and overall, rate of
treatment changes related to UTI, for example,
antibiotic escalations. The hypothesis is that there
are no excess re-hospitalizations or visits to the GP
while there are fewer treatment changes and medical
investigations in the ProADM group.
B. Proportion of patients triaged according to the risk
assessment bundles. The hypothesis is that physician
adherence to site-of-care decisions will be 20%
higher in the intervention group.
C. Functional status (defined by SPI, activities of daily
living and instrumental activities of daily living) and
adverse events (that is the recurrence rate at
30 days, rate of complications (acute renal failure,
ICU requirement, nosocomial infections or
medication side effects), delirium, falls or pressure
ulcers). Our hypothesis is that there is no difference
in the functional status achieved 30 days after
inclusion between the two groups.
D. Patient satisfaction with the provided service and
quality of care at 30 days and 90 days.
E. Healthcare-related quality of life at the day of
discharge as measured with the EQ-5D
questionnaire. The hypothesis for D and E is that
there is no difference in patient satisfaction and
health-related quality of life between the
intervention and the control groups.
F. We will describe the effective and chargeable costs
for the entire treatment pathway in an exploratory
economic analysis.
Endpoints will be assessed at hospital discharge, and
30 and 90 days after admission. An adverse event in a
subject is defined as any untoward occurrence of any
Table 2 Sample size considerations
Time 1 Time 2 Power Alpha-level SD Number per group
10 8 0.8 0.05 4 63
10 8 0.8 0.05 5 99
10 8 0.8 0.05 6 142
10 9 0.8 0.05 4 252
10 9 0.8 0.05 5 393
10 9 0.8 0.05 6 566
6 4.5 0.8 0.05 4 112
6 4.5 0.8 0.05 5 175
6 4.5 0.8 0.05 6 252
6 5 0.8 0.05 4 252
6 5 0.8 0.05 5 393
6 5 0.8 0.05 6 566
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sign, any symptom or any disease temporally associated
with the study, which must not necessarily have a causal
relationship with the study procedure. Any serious unex-
pected adverse event (for example, transfer to ICU, re-
hospitalization, recurrence of an UTI, papillary necrosis,
intrarenal or perirenal abscess, emphysematous pyelo-
nephritis, allergic reaction to contrast medium during
ultrasound or death) within 180 days after study inclu-
sion is monitored by the data safety and monitoring
board (DSMB). All adverse events will be followed until
resolution, until the condition stabilizes, until the event
is otherwise explained or the subject is lost to follow-up.
Sample size
Intervention A
The first co-primary objective is to show that the dur-
ation of antibiotic therapy in the index hospitalization is
2 days shorter in the PCT group (8 days, standard devi-
ation ±5) than in the control group (10 days, standard
deviation ±5). These estimates are based on a historical
control group in our hospital [31,36]. According to these
estimations, 99 patients per arm would provide an 80%
power at the 5% alpha level.
Intervention B
Similarly, for LOS estimation in patients with UTI we
used data from a previous study performed on site at the
Cantonal Hospital of Aarau during 2011, which approxi-
mated 6 days (standard deviation ±4) [36]. Our working
hypothesis is that index hospitalization is 1.5 days
shorter in the ProADM group (4.5 days, standard devi-
ation ±4). According to these estimations, 112 patients
per arm would provide an 80% power at the 5% alpha
level (total sample size 224).
Based on previous research at the Cantonal Hospital
of Aarau, there will be approximately 180 to 200 patients
with UTI in a 12-month period, of which approximately
75 are expected to consent to this trial. Thus we esti-
mate to complete the trial within 36 months.
The necessary sample sizes are shown in Table 2 as-
suming varying differences in LOS and antibiotic dur-
ation between the two intervention groups. Therefore,
we will aim for a sample size of 250.
Statistical considerations
The primary analysis population will be the full analysis
set, which includes all patients following an intention-
to-treat principle. Every effort will be made to keep the
number of losses to follow-up minimal. A sensitivity
analysis will be carried out including only patients with
evaluable primary endpoint data to assess potential bias
due to patients lost to follow-up. Two co-primary end-
points will be used to compare, for Intervention A, theduration of antibiotic therapy and, for Intervention B,
the length of physician-led hospitalization. A secondary
analysis population, the per-protocol population, will be
defined, which excludes major protocol violators. Speci-
fically, patients will be excluded from the per-protocol
population if they fulfill any of the following: violation of
inclusion or exclusion criteria, not treated according to
the trial requirements (that is, overriding of triage rec-
ommendations on admission or on day 3 without a pre-
specified reason) or lost to follow-up. As a sensitivity
analysis, the primary analysis will be repeated on the
subset of patients with evaluable outcomes (that is,
drop-outs are excluded from this additional analysis)
and repeated on the per-protocol population.
To test the two continuous primary endpoints of this
two-by-two factorial design study we will use the
Mann–Whitney U test and calculate a median regression
model [54]. We do not expect an interaction between
the co-primary endpoints (for Intervention A the dur-
ation of antibiotic therapy and for intervention B the
length of stay in our study). In our previous studies we
showed that the shorter duration of antibiotic therapy in
LRTIs did not influence the overall length of stay
[41,55]. However, our algorithm for antibiotic guidance
is different between inpatients and outpatients, which
makes effect modification possible. Therefore we will
formally test for an interaction using the median regres-
sion model. We are aware that the test for an interaction
may result in a false negative due to the low power and
the rather small sample size [56,57].
In a second step, the primary endpoint will be ex-
plored for association with potential prognostic factors
in a median regression model considering potential
confounding factors such as: age, sex, UTI subgroup,
time to reach stability, co-morbidities, patient prefer-
ences and living conditions prior to hospitalization.
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For both interventions, the secondary endpoints will be
compared by the t-test if normally distributed, by the
Mann–Whitney U test if similarly shaped but are not
normally distributed continuous data, by chi-square tests
for categorical data or by the log-rank test for time-
to-event data, as appropriate. Since this is a feasibility
study we will not have enough power to test for non-
inferiority. Estimates of effect size and corresponding
confidence intervals will be provided. Exploratory ana-
lyses of endpoints adjusted for possible confounders will
be performed using linear or logistic regression or Cox
proportional hazards models, as appropriate. Prognostic
accuracy will be assessed by receiver operating charac-
teristic curve analysis and by calculating sensitivity, spe-
cificity, positive and negative predictive values and
likelihood ratios for medical and biopsychosocial risk
assessments.
Discussion
The results of earlier studies by our group provided evi-
dence that antibiotic therapy can be guided in patients
with LRTI using PCT cutoff ranges. We recently showed
that biomarkers, especially ProADM, are able to predict
the outcome for patients with LRTIs [58]. On account of
this, we added the ProADM to the widely used CURB65
score, resulting in the CURB65-A score capable of guid-
ing triage decisions [31,35].
In this study we extend our concepts to patients with
UTI, which contributed approximately 7% of patients in
the previous French multi-center ProRATA study [13].
UTIs, as one of the most common indications for anti-
biotic therapy [59], provide an ideal opportunity for ex-
trapolating our knowledge from LRTI studies.
In the current guidelines [4,10,19] a crucial point in
the determination of the length of antibiotic therapy and
whether a patient has to be hospitalized or not, has been
the distinction between lower and upper UTI, and this
classification is still based on subjective criteria. The first
aim of this study is to create evidence-based guidelines,
which will allow clinicians to administer tailored anti-
biotic therapy in uncomplicated as well as in compli-
cated UTIs by using PCT levels and pyuria dynamics.
This will help to determine the optimal length of anti-
biotic therapies and avoid antibiotic overuse.
As shown in a study among a population of frail elderly
nursing home residents, 43% of all patients receiving anti-
biotic treatment for an assumed UTI are over-diagnosed
and actually do not require antibiotics [60]. Another large
potential for reducing antibiotic use lies in febrile UTI pa-
tients, who currently receive at least 7 days of antibiotics
according to guidelines.
The second aim is to support clinicians in site-of-care
decision-making, for which we will use the ProADMcutoff levels we extracted from our previous trials
[29,31,35,36]. This study can provide proof of our concept,
in that the algorithms we obtained in our LRTI studies
can be adapted to other common infections with only
minor disease-specific adaptations. Given the fact that
UTIs have a high prevalence, any improvement to the
current risk assessment is of both great socio-economic
and scientific interest. Hospital stays are very costly and
avoiding or shortening the LOS could result in large
savings [61]. Clinical severity scores classify patients
according to the presence of co-morbidities and subjective
criteria [45]. Even though recommended in guidelines,
these clinical scores have the disadvantage of being too
general and do not give sufficient weight to the host re-
sponse [50,62]. Adding objective criteria such as easily
measurable biomarkers to these clinical scores individual-
izes medical decisions and might detect subgroups that
have a higher risk of suffering complications and therefore
require increased attention and particular care. On the
other hand, a trustworthy method of identifying patients
with a low risk of adverse events, allows outpatient treat-
ment with lower risk of healthcare-associated infections
[63], as well as treatment in nurse-led care. It gives physi-
cians, nurses, patients and relatives the required confi-
dence in their decisions. Risk-based triage could reduce
bed shortages during peak times and lead to lower costs.
Potential limitations
This protocol describes two randomized open interven-
tion trials in one factorial study design with an expected
high external validity. However, contamination within the
proposed open trial design is obvious. The Hawthorne
effect of an earlier discharge in the intervention group
compared to the control group is possible as well as a
spillover effect since PCT and ProADM values are not
blinded because they are part of the routine chemistry.
However, the bias due to the Hawthorne effect for the
primary endpoints (for Interventions A and B) is
expected to be conservative and favor the null hypoth-
esis. The research team emphasizes treatment and tri-
age algorithms according to the randomized group.
Previous studies showed poor guideline compliance
despite high-intensity implementation. Therefore the
expected spillover effect will also have a conservative
influence on the primary endpoints. We minimize as-
certainment bias by having objective, measurable pri-
mary endpoints. More subjective secondary endpoints
will be assessed by blinded researchers.
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